Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients
Identifieur interne : 001F94 ( Main/Exploration ); précédent : 001F93; suivant : 001F95Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients
Auteurs : Richard M. Camicioli [Canada] ; Thomas P. Bouchard [Canada] ; Martin J. Somerville [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-01-30.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacokinetics), Antiparkinson Agents (therapeutic use), B-Vitamins, B‐vitamins, Cognition, Creatinine (blood), Female, Folic Acid (blood), Genotype, Homocystein, Homocysteine (biosynthesis), Homocysteine (blood), Human, Humans, Inactivation, Metabolic, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (pharmacokinetics), Levodopa (therapeutic use), MTHFR, Male, Methylation, Methylenetetrahydrofolate Reductase (NADPH2) (genetics), Motor Skills, Nervous system diseases, Neuropsychological Tests, Parkinson Disease (blood), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Severity of Illness Index, Vitamin B Complex (administration & dosage), homocysteine, mental status.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa, Vitamin B Complex.
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , biosynthesis : Homocysteine.
- chemical , blood : Creatinine, Folic Acid, Homocysteine.
- chemical , genetics : Methylenetetrahydrofolate Reductase (NADPH2).
- chemical , pharmacokinetics : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- blood : Parkinson Disease.
- physiopathology : Parkinson Disease.
- psychology : Parkinson Disease.
- Aged, Cognition, Female, Genotype, Humans, Inactivation, Metabolic, Male, Methylation, Motor Skills, Neuropsychological Tests, Severity of Illness Index.
Abstract
Levodopa (L‐dopa) treatment of Parkinson's disease (PD) is associated with elevated homocysteine (Hcy). To examine the relationship between Hcy, methylenetetrahydrofolate reductase polymorphisms (MTHFR: 677C/T; 1298A/C), and B‐vitamins in older PD patients and whether Hcy or MTHFR polymorphisms were associated with clinical measures. MTHFR polymorphisms, B‐vitamin intake, and blood concentrations of Hcy, vitamin B12 and folate, and creatinine were determined and compared between groups (PD and controls). The relationship of Hcy to clinical measures was examined in PD. Among 51 patients [30M/21F, mean age (SD): 71.5 (4.7)] and 50 controls [29M/21F, 71.5 (4.8)], Hcy was higher in PD [13.6 (3.8); controls: 10.5 (2.5), P < 0.0005]. Hcy was associated with B‐vitamin intake [F = 21.7, P < 0.0005], folate level (R = 0.31, P = 0.035), and the interaction of intake with MTHFR 677T (F = 5.2, P = 0.007), but not MTHFR 1298C genotype. Hcy did not correlate with global measures of cognition, mood, or parkinsonism in PD or with dyskinesias, fluctuations, or freezing. Higher vitamin B12 levels were associated with lower dyskinesia risk. Hcy was influenced by PD, MTHFR 677 genotype, and vitamin use, but not by the MTHFR 1298 genotype. There was no clear association with motor or cognitive measures, but dyskinesias were less likely with higher B12. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22227
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000343
- to stream Istex, to step Curation: 000343
- to stream Istex, to step Checkpoint: 000770
- to stream PubMed, to step Corpus: 000F03
- to stream PubMed, to step Curation: 000F03
- to stream PubMed, to step Checkpoint: 000F03
- to stream Ncbi, to step Merge: 000973
- to stream Ncbi, to step Curation: 000973
- to stream Ncbi, to step Checkpoint: 000973
- to stream Main, to step Merge: 002147
- to stream PascalFrancis, to step Corpus: 000575
- to stream PascalFrancis, to step Curation: 000717
- to stream PascalFrancis, to step Checkpoint: 000461
- to stream Main, to step Merge: 002265
- to stream Main, to step Curation: 001F94
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients</title><author><name sortKey="Camicioli, Richard M" sort="Camicioli, Richard M" uniqKey="Camicioli R" first="Richard M." last="Camicioli">Richard M. Camicioli</name></author><author><name sortKey="Bouchard, Thomas P" sort="Bouchard, Thomas P" uniqKey="Bouchard T" first="Thomas P." last="Bouchard">Thomas P. Bouchard</name></author><author><name sortKey="Somerville, Martin J" sort="Somerville, Martin J" uniqKey="Somerville M" first="Martin J." last="Somerville">Martin J. Somerville</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8D8D4721F3927D26EFD2C116CBEB0F3684705A37</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22227</idno><idno type="url">https://api-v5.istex.fr/document/8D8D4721F3927D26EFD2C116CBEB0F3684705A37/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000343</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000343</idno><idno type="wicri:Area/Istex/Curation">000343</idno><idno type="wicri:Area/Istex/Checkpoint">000770</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000770</idno><idno type="wicri:doubleKey">0885-3185:2009:Camicioli R:homocysteine:is:not</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18951534</idno><idno type="wicri:Area/PubMed/Corpus">000F03</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F03</idno><idno type="wicri:Area/PubMed/Curation">000F03</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F03</idno><idno type="wicri:Area/PubMed/Checkpoint">000F03</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F03</idno><idno type="wicri:Area/Ncbi/Merge">000973</idno><idno type="wicri:Area/Ncbi/Curation">000973</idno><idno type="wicri:Area/Ncbi/Checkpoint">000973</idno><idno type="wicri:Area/Main/Merge">002147</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0104585</idno><idno type="wicri:Area/PascalFrancis/Corpus">000575</idno><idno type="wicri:Area/PascalFrancis/Curation">000717</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000461</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000461</idno><idno type="wicri:doubleKey">0885-3185:2009:Camicioli R:homocysteine:is:not</idno><idno type="wicri:Area/Main/Merge">002265</idno><idno type="wicri:Area/Main/Curation">001F94</idno><idno type="wicri:Area/Main/Exploration">001F94</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients</title><author><name sortKey="Camicioli, Richard M" sort="Camicioli, Richard M" uniqKey="Camicioli R" first="Richard M." last="Camicioli">Richard M. Camicioli</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine (Neurology), University of Alberta, Edmonton</wicri:regionArea><wicri:noRegion>Edmonton</wicri:noRegion></affiliation><affiliation></affiliation></author><author><name sortKey="Bouchard, Thomas P" sort="Bouchard, Thomas P" uniqKey="Bouchard T" first="Thomas P." last="Bouchard">Thomas P. Bouchard</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine (Neurology), University of Alberta, Edmonton</wicri:regionArea><wicri:noRegion>Edmonton</wicri:noRegion></affiliation></author><author><name sortKey="Somerville, Martin J" sort="Somerville, Martin J" uniqKey="Somerville M" first="Martin J." last="Somerville">Martin J. Somerville</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Genetics, University of Alberta, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-01-30">2009-01-30</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="176">176</biblScope><biblScope unit="page" to="182">182</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8D8D4721F3927D26EFD2C116CBEB0F3684705A37</idno><idno type="DOI">10.1002/mds.22227</idno><idno type="ArticleID">MDS22227</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Antiparkinson Agents (therapeutic use)</term><term>B-Vitamins</term><term>B‐vitamins</term><term>Cognition</term><term>Creatinine (blood)</term><term>Female</term><term>Folic Acid (blood)</term><term>Genotype</term><term>Homocystein</term><term>Homocysteine (biosynthesis)</term><term>Homocysteine (blood)</term><term>Human</term><term>Humans</term><term>Inactivation, Metabolic</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Levodopa (pharmacokinetics)</term><term>Levodopa (therapeutic use)</term><term>MTHFR</term><term>Male</term><term>Methylation</term><term>Methylenetetrahydrofolate Reductase (NADPH2) (genetics)</term><term>Motor Skills</term><term>Nervous system diseases</term><term>Neuropsychological Tests</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (psychology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Severity of Illness Index</term><term>Vitamin B Complex (administration & dosage)</term><term>homocysteine</term><term>mental status</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term><term>Vitamin B Complex</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Homocysteine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Creatinine</term><term>Folic Acid</term><term>Homocysteine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Methylenetetrahydrofolate Reductase (NADPH2)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cognition</term><term>Female</term><term>Genotype</term><term>Humans</term><term>Inactivation, Metabolic</term><term>Male</term><term>Methylation</term><term>Motor Skills</term><term>Neuropsychological Tests</term><term>Severity of Illness Index</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Homme</term><term>Homocystéine</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Vitamine B</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa (L‐dopa) treatment of Parkinson's disease (PD) is associated with elevated homocysteine (Hcy). To examine the relationship between Hcy, methylenetetrahydrofolate reductase polymorphisms (MTHFR: 677C/T; 1298A/C), and B‐vitamins in older PD patients and whether Hcy or MTHFR polymorphisms were associated with clinical measures. MTHFR polymorphisms, B‐vitamin intake, and blood concentrations of Hcy, vitamin B12 and folate, and creatinine were determined and compared between groups (PD and controls). The relationship of Hcy to clinical measures was examined in PD. Among 51 patients [30M/21F, mean age (SD): 71.5 (4.7)] and 50 controls [29M/21F, 71.5 (4.8)], Hcy was higher in PD [13.6 (3.8); controls: 10.5 (2.5), P < 0.0005]. Hcy was associated with B‐vitamin intake [F = 21.7, P < 0.0005], folate level (R = 0.31, P = 0.035), and the interaction of intake with MTHFR 677T (F = 5.2, P = 0.007), but not MTHFR 1298C genotype. Hcy did not correlate with global measures of cognition, mood, or parkinsonism in PD or with dyskinesias, fluctuations, or freezing. Higher vitamin B12 levels were associated with lower dyskinesia risk. Hcy was influenced by PD, MTHFR 677 genotype, and vitamin use, but not by the MTHFR 1298 genotype. There was no clear association with motor or cognitive measures, but dyskinesias were less likely with higher B12. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Camicioli, Richard M" sort="Camicioli, Richard M" uniqKey="Camicioli R" first="Richard M." last="Camicioli">Richard M. Camicioli</name></noRegion><name sortKey="Bouchard, Thomas P" sort="Bouchard, Thomas P" uniqKey="Bouchard T" first="Thomas P." last="Bouchard">Thomas P. Bouchard</name><name sortKey="Somerville, Martin J" sort="Somerville, Martin J" uniqKey="Somerville M" first="Martin J." last="Somerville">Martin J. Somerville</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F94 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F94 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8D8D4721F3927D26EFD2C116CBEB0F3684705A37
|texte= Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients
}}
| This area was generated with Dilib version V0.6.29. |  |